RIVERVEST NEWSLETTER

February 2026 Issue

RiverVest invites you to read our latest newsletter, featuring:

  • Portfolio Company Bluejay Therapeutics Acquired by Mirum              
  • Pharmaceuticals
  • JPM 2026 Recap: Signals are Getting Clearer
  • RiverVest Scientific Advisor Alessandro Sette to Receive Prestigious           Immunology Award
  • Could Excess Cortisol Be Driving Type 2 Diabetes Resistance?
  • Portfolio News

RiverVest News features insights and updates on the Science, Strategy, and Innovation behind our investments. 

 

 Subscribe to our newsletter (delivered to your email inbox three times per year)

 

  Read Past Issues of RiverVest News  (Newsletter Archive)

About RiverVest

RiverVest Venture Partners is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors. With headquarters in St. Louis and offices in San Diego and Cleveland, RiverVest accesses forward-thinking research and clinical expertise at leading institutions across the country to found and fund biopharma and medical device companies.

Paragraph